Experimental study suggests bone-marrow grafts show promise for some sufferers of low-back pain

April 11, 2013

A new study suggests that the type of bio-cellular grafts increasingly used by surgeons to repair damaged tissue may be useful for treating low-back pain (LBP). However, not all sufferers responded equally to the novel therapy. Results reported today at the 29th Annual Meeting of the American Academy of Pain Medicine ranged from complete pain relief to no improvement.

The procedure involved injecting a concentrated form of bone-marrow cellular aspirate into lumbar discs in patients with clinical and objective evidence of . The results were reported in a poster authored by researchers from the Columbia Interventional Center in Columbia, Mo., and the Bluetail Medical Group in Chesterfield, Mo.

"The results of our case review are encouraging," said Donald J. Meyer, MD, PhD, the study's primary author. "Currently, when measures fail, are limited for individuals with back pain due to disc degeneration. Many resort to disc surgery or with mediocre results. Our goal is to help develop a safe, natural method to boost the body's own capacity to heal discogenic pain."

The practice of using autologous grafts, in which material is transferred from within the same individual's body, has evolved beyond the simple use of platelet-rich plasma to encompass cellular bone-marrow concentrate and cells drawn from body fat, the study authors explained. Intrigued by the technique's possibilities in treating LBP, the team retrospectively examined data for 22 consecutive patients treated at Columbia Interventional Pain Center in Columbia, Mo., over 18 months. Patients had LBP lasting an average of 4 years along with evidence confirming changes via CT scan or MRI. Some patients also complained of leg pain.

Patients were informed of the study's experimental nature and gave informed consent. During the procedure, investigators harvested 60 cc iliac bone-marrow aspirate and concentrated it in a centrifuge to obtain bone-marrow aspirate cellular concentrate (BMAC). They then injected BMAC into each affected lumbar disc annulus using a 22-gauge Chiba needle under fluoroscopy. This was followed by the injection of an additional small amount of BMAC immediately external to the annulus. A maximum of 2 discs were treated.

At 5-24 months following treatment, patients reported changes in back pain ranging from complete pain relief to no improvement. No patient reported a worsening of pain, and no complications occurred. All subjects who experienced pain relief also reported significant improvement in activity tolerance or a reduction in pain medication use, or both.

A future prospective study is warranted, the authors concluded, to examine whether biologic autograft treatment may provide a safe and effective therapy for lumbar discogenic pain.

Related Stories

Pattern of disc degeneration impacts low back pain

April 12, 2012

(HealthDay) -- Contiguous, multilevel disc degeneration (CMDD) is associated with increased likelihood of low back pain (LBP) and pain severity compared with skipped level disc degeneration (SLDD), according to a study published ...

Spanish registry IDs predictors of low back pain improvement

December 20, 2012

(HealthDay)—For patients with acute or chronic low back pain (LBP), predictors have been identified for clinically relevant improvements in LBP, pain down the leg (LP), and disability at three months, according to research ...

Upper lumbar disc space related to hip pain

December 21, 2012

(HealthDay)—Disc space narrowing at disc levels L1/L2 and L2/L3, visible on lumbar radiographs, may help to identify hip pain patients whose pain originates in the lumbar spine, according to research published in the November ...

Spine patients who quit smoking report diminished pain

March 19, 2013

Smoking is a known risk factor for back pain and disc disease. In a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), researchers reviewed smoking cessation rates ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.